Legal Representation
Attorney
Frances M. Jagla
USPTO Deadlines
Next Deadline
396 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-09-01)
Due Date
September 01, 2026
Grace Period Ends
March 01, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
36 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 28, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 28, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 28, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Nov 28, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Nov 28, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Sep 17, 2021 | COC. | O | CORRECTION UNDER SECTION 7 - PROCESSED | Loading... |
| Sep 16, 2021 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | Loading... |
| Jul 7, 2021 | PRAM | O | POST REGISTRATION ACTION MAILED - SEC. 7 | Loading... |
| Jul 6, 2021 | PRAM | O | POST REGISTRATION ACTION MAILED - SEC. 7 | Loading... |
| Jul 6, 2021 | PRAM | O | POST REGISTRATION ACTION MAILED - SEC. 7 | Loading... |
| Jul 6, 2021 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
| Mar 11, 2021 | AMD7 | I | SEC 7 REQUEST FILED | Loading... |
| Mar 11, 2021 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED | Loading... |
| Sep 1, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 25, 2020 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jul 24, 2020 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jul 23, 2020 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jul 23, 2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jul 2, 2020 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jul 2, 2020 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Feb 11, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 17, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 17, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 27, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 12, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Nov 6, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 6, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 5, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Nov 5, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 21, 2019 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | Loading... |
| Aug 21, 2019 | GPRA | F | PRIORITY ACTION E-MAILED | Loading... |
| Aug 21, 2019 | CPRA | R | PRIORITY ACTION WRITTEN | Loading... |
| Aug 19, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 14, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jun 13, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 1, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
SCIENTIFIC RESEARCH, PHARMACEUTICAL RESEARCH, MEDICAL RESEARCH; TECHNICAL AND SCIENTIFIC CONSULTATION AND PRODUCT DEVELOPMENT SERVICES FOR OTHERS, IN THE FIELD OF IMMUNE MEDIATED DISEASES, INFLAMMATORY DISEASES, AND RARE DISEASES; RESEARCH AND DEVELOPMENT OF NEW PRODUCTS PERTAINING TO THE TREATMENT OF IMMUNE MEDIATED DISEASES, INFLAMMATORY DISEASES, AND RARE DISEASES, AND TO PHARMACEUTICALS; PROVIDING ON-LINE INFORMATION FOR MEDICAL RESEARCH PURPOSES, IN THE FIELDS OF IMMUNE MEDIATED DISEASES, INFLAMMATORY DISEASES, AND RARE DISEASES, TREATMENTS FOR IMMUNE MEDIATED DISEASES, INFLAMMATORY DISEASES, AND RARE DISEASES, AND PHARMACEUTICALS
First Use Anywhere:
May 10, 2016
First Use in Commerce:
May 10, 2016
Additional Information
Design Mark
The mark consists of the word "Protagonist" in black above the word "Therapeutics" in orange to the right of the words is a DNA double helix in the colors black and orange. The entire mark is on a transparent background.
Color Claim
The color(s) black and orange is/are claimed as a feature of the mark.
Other
In the statement, line 1, "CALIFORNIA" should be deleted, and "DELAWARE" should be inserted.
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"